

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-211 (TRYPTYR[®] acoltremon eye drop) has completed the enrollment of a total of 398 patients for its phase III clinical trial in the People’s Republic of China (the “**PRC**”) recently.

OT-211 (TRYPTYR[®] acoltremon eye drop) is a 0.003% concentration eye drop formulation and the first TRPM8 agonist approved by the U.S. Food and Drug Administration (“**FDA**”) for the treatment of dry eye disease (“**DED**”). In March 2026, the phase III clinical trial of OT-211 in the PRC enrolled its first patient, marking an important milestone in the clinical development of OT-211 in the PRC and demonstrating the Group’s commitment to advancing innovative therapies for DED patients.

Alcon Inc. (together with its subsidiaries, the “**Alcon Group**”), the global leader in eye care with complementary businesses in surgical and vision care, developed the 0.003% concentration eye drop formulation of AR-15512 and completed one phase IIb and three phase III clinical trials. OT-211 was approved by the FDA on May 28, 2025 for the treatment of the signs and symptoms of DED. The Group, after the strategic cooperation with Alcon Group in October 2024, obtained an exclusive license from the Alcon Group to develop, make, have made, import, export and sell OT-211 in Chinese Mainland. The successful enrollment for OT-211 marks that the Company and Alcon Group have also established a strong collaborative and binding partnership in the field of new drug development, laying the foundation for the subsequent joint exploration and development of new drugs.

Cautionary Statement: The Company cannot guarantee that it will be able to successfully develop or ultimately commercialize OT-211 (TRYPTYR® acoltremon eye drop). Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 2, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.